-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UV-1 in Hormone-Sensitive Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UV-1 in Hormone-Sensitive Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. UV-1 in Hormone-Sensitive Prostate Cancer Drug Details: UV-1 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UV-1 in Malignant Pleural Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UV-1 in Malignant Pleural Mesothelioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. UV-1 in Malignant Pleural Mesothelioma Drug Details: UV-1 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UV-2 in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UV-2 in Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. UV-2 in Prostate Cancer Drug Details: UV-2 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Epithelial Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Epithelial Ovarian Cancer Drug Details: Durvalumab (MEDI-4736, Imfinzi,...
-
Product Insights
Hormone-Sensitive Prostate Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Hormone-Sensitive Prostate Cancer - Drugs In Development, 2023’, provides an overview of the Hormone-Sensitive Prostate Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hormone-Sensitive Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Malignant Pleural Mesothelioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Malignant Pleural Mesothelioma - Drugs In Development, 2023’, provides an overview of the Malignant Pleural Mesothelioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Malignant Pleural Mesothelioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Drugs In Development, 2023’, provides an overview of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UV-1 in Epithelial Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. UV-1 in Epithelial Ovarian Cancer Drug Details: UV-1 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pirenzepine in Diabetic Peripheral Neuropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pirenzepine in Diabetic Peripheral Neuropathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Pirenzepine in Diabetic Peripheral Neuropathy Drug Details:Pirenzepine (WST-057) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UV-1 in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UV-1 in Fallopian Tube Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.UV-1 in Fallopian Tube Cancer Drug Details:UV-1 is under development for the...